Drug Trial Radar · NCT03292133
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Oct 31, 2017
Primary completion
Dec 31, 2021
Study completion Mar 4, 2025
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Sep 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: * EGF816 * Gefitinib
Conditions
- Lung Cancer
Interventions
EGF816Drug
EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
GefitinibDrug
Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
Primary outcomes
What the sponsor says the trial is designed to measure.
- 9 Months Progression Free RateTime frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.